25mg tirzepatide: does this dose exist, and what does the highest licensed strength actually do?

You've seen "25mg" on a weight-loss forum, here's what that actually refers to

It's a reasonable thing to search for. Posts comparing injectable tirzepatide and the newer oral options often list doses side by side without making clear they belong to completely different medicines. The 25mg figure belongs to Wegovy tablets (oral semaglutide) which the MHRA approved in June 2026 as the UK's first oral GLP-1 medicine licensed for weight management. Its titration runs 1.5mg, 4mg, 9mg, then 25mg, taken daily as the first thing in the morning on an empty stomach.

If you want to understand how tirzepatide works as a treatment, sold in the UK as Mounjaro, it is a once-weekly subcutaneous injection and its dose ladder tops out at 15mg. The two medicines work on related but distinct mechanisms: tirzepatide activates both the GIP and GLP-1 receptors, while semaglutide targets GLP-1 alone. That pharmacological difference partly explains why their trial results, and their dose numbers, look so different.

So if you were searching because you'd seen 25mg described as the most effective option for weight loss, you weren't wrong to look further. You were just looking at two medicines at once without a label telling you which was which. Worth knowing before you pick up the phone to a prescriber.

What tirzepatide's actual top dose (15mg) delivers in practice

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed adults with obesity over 72 weeks. At the 15mg dose, participants lost an average of around 20–21% of their body weight. That figure has driven most of the clinical interest in tirzepatide since NICE recommended it for NHS use in December 2024.

Reaching 15mg is not a starting point. Treatment opens at 2.5mg, which exists to let your digestive system adjust, the gastrointestinal side effects (nausea, loose stools, indigestion) are most pronounced in the early weeks and the titration is designed to reduce their impact. Dose increases happen roughly every four weeks, and they're guided by how you're tolerating the current pen, not by a rigid calendar. Some people stay at an intermediate dose for longer. A prescriber decides when to move up, and the goal is the highest dose you tolerate well rather than 15mg as an automatic destination.

If you're curious about how pricing shifts across the dose range, the Mounjaro cost page covers that in detail. Private treatment is priced per pen, and the list price rose significantly in September 2025, so it's worth understanding what's included before you compare figures.

Why the comparison between tirzepatide and 25mg oral semaglutide matters clinically

The SURMOUNT-5 trial compared tirzepatide directly with semaglutide 2.4mg (the injectable form) over 72 weeks and found tirzepatide produced greater average weight reduction. The oral semaglutide trial, OASIS 4, reported around 13.6% average weight loss at the 25mg dose over 64 weeks among people with obesity or overweight, closer to injectable semaglutide's earlier results than to tirzepatide's.

That doesn't make one medicine objectively better for everyone. Oral dosing removes needles entirely, which matters to a lot of people. Tirzepatide requires refrigeration; tablets don't, which makes travel and daily routine simpler. Some people do better tolerating one than the other. If you are weighing up the tirzepatide l pen options against oral alternatives, whether you already take an injectable, whether you have other health conditions, and what medications you use all shape the clinical picture considerably.

The Mounjaro vs tirzepatide explainer covers the brand and generic name relationship if you've found the naming confusing. For a broader look at what the evidence shows across licensed weight-loss treatments, the treatment overview is a useful reference point.

Getting the right prescription: what a clinical assessment actually covers

Because both medicines are prescription-only, no legitimate route to either starts with choosing a dose number from a forum. A prescriber needs your weight (verified, not self-reported, at nume this happens on a brief video call), your medical history, any medications you take, and whether you have conditions that affect which treatment is appropriate.

Tirzepatide is licensed for adults with a BMI of 30 or above, or 27 or above if you have at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. Oral semaglutide follows similar criteria. You can find further detail on pen strengths, including information about the tirzepatide 30 supply format, through the NICE appraisal; the NICE appraisal of tirzepatide (TA1026) sets out the NHS eligibility criteria in detail, and private prescribing through a regulated pharmacy is available to people who meet the licensed criteria but don't meet the NHS thresholds or prefer not to wait.

If you're unsure which of these medicines suits your situation, or whether either is appropriate, that's exactly the kind of question our prescribers work through with you. There's no pressure toward a particular pen or tablet, the clinical picture decides it. Speak to our prescribers through a free consultation and get a clear answer based on your actual health information.